Your browser doesn't support javascript.
loading
Clinical study on the treatment of early diabetic nephropathy with hyperuricemia by low dose spironolactone combined with febuxostat / 中国生化药物杂志
Article Dans Zh | WPRIM | ID: wpr-614072
Responsable en Bibliothèque : WPRO
ABSTRACT
Objective To ivaluate the effect of low dose spironolactone combined with febuxostat on the treatment of early diabetic nephropathy complicated with hyperuricemia, in order to provide guidance for clinical.Methods206 cases with early diabetic nephropathy complicated with hyperuricemia in Zhongshan hospital affiliated to Fudan University from June 2013 to June 2014, were randomly divided into the control group and the experimental group, 103 cases in each group.The 2 groups were treated with oral hypoglycemic drugs or insulin to control blood sugar, low salt, low fat and low protein diet.At this basis, the control group were treated with low dose of spironolactone, the experimental group were given low dose spironolactone combined with febuxostat, 24 weeks for a course of treatment.The disease related indexes in the two groups were compared before and after treatment.ResultsAfter treatment, the HbAlc, SUA, TC, TG, UAER and the whole blood viscosity were significantly decreased in the experimental group (P<0.05).There was no significant difference among the indexes in the control group before and after treatment.UAER and SUA in the experiment were lower than those in the control group after treatment (P< 0.05), and the differences of HbAlc, TC, TG, HDL-C, LDL-C and hemorheology index in the two groups were not statistically significant.ConclusionBased on the control of blood glucose and diet therapy, it can correct hyperuricemia, regulate blood sugar and blood lipid disorders, correct the hemorheological indexes, which low doses of spironolactone combined with febuxostat in treating early diabetic nephropathy complicated with hyperuricemia, it can protect renal function well, and it is worthy of attention and promotion.

Texte intégral: 1 Indice: WPRIM Type d'étude: Guideline langue: Zh Texte intégral: Chinese Journal of Biochemical Pharmaceutics Année: 2017 Type: Article
Texte intégral: 1 Indice: WPRIM Type d'étude: Guideline langue: Zh Texte intégral: Chinese Journal of Biochemical Pharmaceutics Année: 2017 Type: Article